Features

Pricing the EpiPen: Drug Prices, Corporate Governance, and the Financialization of Biomedicine

Why does Mylan’s EpiPen cost so much?

That was a question many parents of food allergic children found themselves asking this past August, as a flurry of news reports revealed that the standard two-pack now costs patients as much as $600 out of pocket. The device, a type of epinephrine auto-injector, looks like an oversized marker. Inside is a …

Web Roundups

Web Roundup: Controversy and Commerce

There have been many controversies about substantial and sudden jumps in pharmaceutical prices, the most memorable/infamous surrounding Martin Shkreli, the [widely despised and thoroughly unrepentant] former CEO of the drug company Turing, and the 5000% increase in the price of a drug used by many AIDS patients. Similar questions of impropriety have been raised by the practices …

Features

Manufacturing neglect: What happens to drugs once the epidemic has passed?

This article is part of the series:

We like to think that drugs help put an end to disease, although in the aggregate this is seldom the case. However many individual infections and infestations might have been cured by timely doses of antibiotics, antifungals, antiparasitics, or antivirals, very few diseases have been eradicated because of biomedical therapeutics. Yaws, a chronic treponemal disease now limited to 14 countries …